NASDAQ:CDXS

Codexis (CDXS) Stock Forecast, Price & News

$1.70

+0.15 (+9.68%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.55
▼
$1.71
50-Day Range: $1.50
▼
$3.75
52-Week Range: $1.45
▼
$6.98

Volume: 862,466 shs
Average Volume: 878,278 shs
Market Capitalization: $118.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.83

Codexis MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 362.1% Upside
$7.83 Price Target
Short Interest: Healthy
3.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -3.67
Upright™ Environmental Score
News Sentiment: 0.84
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$55,403 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.96) to ($0.69) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

256th out of 975 stocks

Industrial Organic Chemicals Industry

5th out of 19 stocks

3.3

Analyst's Opinion

Consensus Rating
Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.83, Codexis has a forecasted upside of 362.1% from its current price of $1.70.
Amount of Analyst Coverage
Codexis has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.44% of the outstanding shares of Codexis have been sold short.
Short Interest Ratio / Days to Cover
Codexis has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Codexis has recently increased by 1.69%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Codexis does not currently pay a dividend.
Dividend Growth
Codexis does not have a long track record of dividend growth.

2.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Codexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Codexis is -3.67.

3.2

News and Social Media Coverage

News Sentiment
Codexis has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Codexis this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
4 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Codexis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,403.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Codexis is held by insiders.
Percentage Held by Institutions
87.94% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Codexis are expected to grow in the coming year, from ($0.96) to ($0.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Codexis is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Codexis is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Codexis has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Price History

30 days | 90 days | 365 days | Advanced Chart

CDXS Stock News Headlines

September 27, 2023 | americanbankingnews.com

Codexis (NASDAQ:CDXS) Raised to "Hold" at StockNews.com

September 20, 2023 | americanbankingnews.com

Codexis (NASDAQ:CDXS) Lowered to Sell at StockNews.com

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 18, 2023 | finance.yahoo.com

Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award

September 13, 2023 | marketwatch.com

Codexis Stock Climbs After Executives Buy Up Shares

September 13, 2023 | msn.com

Codexis shares up after CFO buys 11,650 shares

September 13, 2023 | finance.yahoo.com

Insider Buying: Kevin Norrett Acquires 9,000 Shares of Codexis Inc (CDXS)

September 12, 2023 | finance.yahoo.com

Codexis to Participate in Cantor Global Healthcare Conference

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 8, 2023 | bizjournals.com

Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic

September 8, 2023 | msn.com

Codexis announces a San Carlos facility lease that could potentially save $30M

September 8, 2023 | finance.yahoo.com

Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease

September 2, 2023 | nasdaq.com

Benchmark Reiterates Codexis (CDXS) Buy Recommendation

August 14, 2023 | msn.com

Stifel Maintains Codexis (CDXS) Buy Recommendation

August 8, 2023 | finance.yahoo.com

BlackRock Inc. Acquires Significant Stake in Codexis Inc.

August 5, 2023 | fool.com

Codexis (NASDAQ: CDXS)

August 4, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Technology Companies: Codexis (CDXS), Clearfield (CLFD) and Climb Global Solutions (CLMB)

August 3, 2023 | finance.yahoo.com

Codexis Reports Second Quarter 2023 Financial Results

July 31, 2023 | finance.yahoo.com

Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics

July 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Infosys (INFY) and Codexis (CDXS)

July 22, 2023 | msn.com

Stephens & Co. Reiterates Codexis (CDXS) Overweight Recommendation

July 21, 2023 | benzinga.com

Codexis' Strategic Focus: Discontinues Biotherapeutics Development, Lays Off 25% Of Employees, Cash Runway Into Mid-2026

July 21, 2023 | seekingalpha.com

Codexis streamlining operations, reducing headcount

July 20, 2023 | bizjournals.com

Codexis pulls back from biotherapeutics as it cuts staff by 25%

July 20, 2023 | markets.businessinsider.com

Craig-Hallum Keeps Their Buy Rating on Codexis (CDXS)

July 11, 2023 | finance.yahoo.com

2 ‘Strong Buy’ Penny Stocks With Massive 300% Upside Potential — Or More

July 10, 2023 | finance.yahoo.com

Codexis (NASDAQ:CDXS) shareholders have endured a 82% loss from investing in the stock five years ago

See More Headlines

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings: 8/03/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Industrial organic chemicals
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CDXS
CUSIP: 19200510
CIK: 1200375
Web: www.codexis.com
Phone: (650) 421-8100
Fax: 650-421-8102
Employees: 248
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.83
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +376.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,590,000.00
Net Margins: -57.22%
Pretax Margin: -57.04%
Return on Equity: -41.33%
Return on Assets: -24.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.36
Quick Ratio: 3.30

Sales & Book Value

Annual Sales: $138.59 million
Price / Sales: 0.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.20 per share
Price / Book: 0.75

Miscellaneous

Outstanding Shares: 69,800,000
Free Float: 65,406,000
Market Cap: $114.82 million
Optionable: Optionable
Beta: 1.79

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Stephen George Dilly MBBS (Age 63)
Ph.D., Pres, CEO & Director
Comp: $753.61k

Mr. Kevin Norrett M.B.A. (Age 50)
M.S., Chief Operating Officer
Comp: $507.28k

Ms. Margaret Fitzgerald J.D. (Age 52)
Chief Legal and Compliance Officer, Gen. Counsel & Sec.
Comp: $300.03k

Mr. Sriram Ryali M.B.A. (Age 41)
Chief Financial Officer

Carrie McKim
Director of Investor Relations

Ms. Karen Frechou-Armijo
Sr. VP & Head of HR

Dr. Stefan Lutz Ph.D.
Sr. VP of Research

Mr. Robert Sato M.B.A.
Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.
What is Codexis' stock price forecast for 2023?: 6 Wall Street analysts have issued 1 year target prices for Codexis' shares. Their CDXS share price forecasts range from $4.00 to $14.00. On average, they anticipate the company's share price to reach $7.83 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.
How have CDXS shares performed in 2023?: Codexis' stock was trading at $4.66 at the start of the year. Since then, CDXS stock has decreased by 64.7% and is now trading at $1.6450.
View the best growth stocks for 2023 here.
When is Codexis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CDXS earnings forecast.
How were Codexis' earnings last quarter?: Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The biotechnology company earned $21.32 million during the quarter, compared to analyst estimates of $19.83 million. Codexis had a negative net margin of 57.22% and a negative trailing twelve-month return on equity of 41.33%. The business's revenue was down 44.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share.
What ETFs hold Codexis' stock?: ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG).Inspire Small/Mid Cap ETF (ISMD).
What guidance has Codexis issued on next quarter's earnings?: Codexis updated its earnings guidance on Monday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.00 million-$22.00 million, compared to the consensus revenue estimate of $18.09 million.
What is John J. Nicols' approval rating as Codexis' CEO?: 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).
What is Codexis' stock symbol?: Codexis trades on the NASDAQ under the ticker symbol "CDXS."
Who are Codexis' major shareholders?: Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.46%), Baillie Gifford & Co. (9.20%), ARK Investment Management LLC (6.18%), Nuveen Asset Management LLC (2.58%), Geode Capital Management LLC (1.92%) and State Street Corp (1.82%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly.
View institutional ownership trends.
How do I buy shares of Codexis?: Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Codexis' stock price today?: One share of CDXS stock can currently be purchased for approximately $1.65.
How much money does Codexis make?: Codexis (NASDAQ:CDXS) has a market capitalization of $114.82 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.
How many employees does Codexis have?: The company employs 248 workers across the globe.
How can I contact Codexis?: Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial